within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP09_Dasabuvir;

model Dasabuvir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.807,
    Cl = 1.7972222222222223e-06,
    adminDuration = 600,
    adminMass = 250 / 1000000,
    adminCount = 1,
    Vd = 0.0476,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.021666666666666667,
    Tlag = 10.020000000000001,
    Vdp = 0.07690000000000001,
    k12 = 3.6666666666666666e-06,
    k21 = 3.6666666666666666e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dasabuvir</td></tr><tr><td>ATC code:</td><td>J05AP09</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>250</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>47.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.47</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dasabuvir is a non-nucleoside NS5B polymerase inhibitor used in combination with other antiviral agents for the treatment of chronic hepatitis C virus (HCV) infection, specifically genotypes 1a and 1b. It was approved as part of fixed-dose combination therapies (such as Viekira Pak) but is no longer widely marketed following advances in HCV therapies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects after single oral administration of dasabuvir.</p><h4>References</h4><ol><li><p>Mensing, S, et al., &amp; Dutta, S (2016). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. <i>The AAPS journal</i> 18(1) 270–280. DOI:<a href=\"https://doi.org/10.1208/s12248-015-9846-1\">10.1208/s12248-015-9846-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26597291/\">https://pubmed.ncbi.nlm.nih.gov/26597291</a></p></li><li><p>Gentile, I, et al., &amp; Borgia, G (2014). Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection. <i>Reviews on recent clinical trials</i> 9(2) 115–123. DOI:<a href=\"https://doi.org/10.2174/1574887109666140529222602\">10.2174/1574887109666140529222602</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24882169/\">https://pubmed.ncbi.nlm.nih.gov/24882169</a></p></li><li><p>Lam, JT, &amp; Salazar, L (2016). New combination antiviral for the treatment of hepatitis C. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 73(14) 1042–1050. DOI:<a href=\"https://doi.org/10.2146/ajhp150163\">10.2146/ajhp150163</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27217519/\">https://pubmed.ncbi.nlm.nih.gov/27217519</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AP09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dasabuvir;
